Here is the latest stock price and chart of DR LALCHANDANI LABS. For more details, see the DR LALCHANDANI LABS company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Must See: Do You Invest in Midcap Stocks? Here's a Great News for You
Live BSE Quotes | Apr 12, 2024 (Close) | ||
---|---|---|---|
Price (Rs)20.85 | Open (Rs) 21.00 | High (Rs) 21.00 | Low (Rs) 20.81 |
% Change-4.79 | Volume 12,000 | Value (Rs) 250,640 | 52-Week H/L 35.00 / 15.68 |
Live NSE Quotes |
---|
Not listed |
Change | |||||
---|---|---|---|---|---|
1 Day -4.79% |
Valuation | ||||
---|---|---|---|---|
EPS (Rs)* - | P/E Ratio (x) - | Market Cap (Rs m) 90.35 | P/BV (x) 1.01 | Dividend Yield (%) 0.00 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
S&P BSE SENSEX
|
||||||
PERIOD |
As of September 2023, company promoters held 60.78% stake in , with no shares having been pledged. To know more, check out the latest shareholding pattern of .
The last traded price of DR LALCHANDANI LABS was Rs 20.9 on the BSE, down 4.8% over the previous close.
The current market capitalisation of DR LALCHANDANI LABS stands at Rs 90 m.
Based on marketcap, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks ranked by marketcap here.
Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.
Based on sales, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks.
Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.
Based on net profit, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks.
In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.
After opening the day deep in red, Indian share markets reversed the trend as the session progressed and ended on firm footing.